CLEERLY

Cleerly's AI-based platform works with coronary computed tomography angiography (CCTA) imaging to help providers diagnose and treat heart disease earlier. 

Cleerly measures the plaque buildup on the heart’s arteries rather than indirect markers such as risk factors and symptoms. The technology’s ability to analyze and characterize different types of plaque can help clinicians more accurately determine a patient’s risk of heart attack. 

New York-based Cleerly has been on a mission to transform cardiac care since its founding in 2017. It has enjoyed a huge 2022, raising a fresh round of $223 million in July for its AI-based approach to translate advanced imaging science into a new approach for identifying people at risk of heart attacks. 

According to a company press release, the research that evolved into Cleerly’s technologies was conducted in The Dalio Institute for Cardiovascular Imaging at the New York-Presbyterian Hospital and Weill Cornell Medicine, including large-scale clinical trials with more than 50,000 patients. It comprised the most extensive body of coronary imaging research to study how imaging can be used to better understand heart disease and project patient outcomes.